Literature DB >> 26541822

Impact of intrafractional respiratory-induced prostate mobility on PTV size.

Dawid Bodusz1, Leszek Miszczyk1.   

Abstract

PURPOSE: Daily image-guided radiation therapy significantly reduces setup errors, but it does not minimize intrafractional target mobility; respiratory-induced target motion is one of the reasons for this. Therefore, the main aim of this study was to evaluate the impact of respiratory-induced prostate motion on the clinical target volume (CTV) margins.
METHODS: The analysis comprised 50 videos stored in digital format and recorded in a group of 50 patients during image-guided radiation therapy for prostate cancer. Fluoroscopy time was 10 seconds. Respiratory motion of the prostate in the anterior-posterior and lateral direction was assessed on the basis of a fiducial marker (GoldAnchor) implanted into the prostate before the treatment planning procedure.
RESULTS: The average values and standard deviations of respiratory-induced prostate motion in the superior-inferior and left-right (lateral) directions were 2.6 ± 2.1 mm and 0.7 ± 0.7 mm, respectively. The CTV margins calculated according to the van Herk formula based on respiratory prostate motion were 8 mm in the superior-inferior direction and 2 mm in the lateral direction.
CONCLUSIONS: Respiratory-induced prostate mobility during radiotherapy is significant especially in the superior-inferior direction, and can thus induce a geographical error. This confirms the need for determining CTV margins for this type of respiratory-induced mobility.

Entities:  

Mesh:

Year:  2015        PMID: 26541822     DOI: 10.5301/tj.5000446

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916            Impact factor:   2.098


  1 in total

1.  Intrafraction Prostate Motion Management for Ultra-Hypofractionated Radiotherapy of Prostate Cancer.

Authors:  Christoph Oehler; Nina Roehner; Marcin Sumila; Jürgen Curschmann; Fabrizio Storelli; Daniel Rudolf Zwahlen; Uwe Schneider
Journal:  Curr Oncol       Date:  2022-08-31       Impact factor: 3.109

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.